Aceriphyllum rossii Exerts Lipid-Lowering Action in Both Normal and Hyperlipidemic Mice

This study aimed to evaluate the lipid-lowering effect of the MeOH extract of Aceriphyllum rossii and its CHCI3 fraction, as well as its inhibitory activity on DGAT in vitro, in normal and hyperlipidemic mice. We separated the MeOH extract of A. rossii into two portions, a CHCI3-soluble part and the remaining water residue, and performed DGAT enzymatic activity assay on them. Further assessment carried out to reveal that the MeOH extract and its CHCI3 fraction suppress the intestinal TG absorption after an acute lipid challenge, and ameliorate hyperlipidemia as well as obesity-related parameters (body weight gain, serum lipid profiles, and several adipose tissue weights) in HFD-induced obese mice. First, the MeOH extract and its CHCI3 fraction strongly inhibit DGAT1 and DGAT2 in vitro enzymatic activity. Second, the MeOH extract and the CHCI3 fraction inhibit intestinal TG absorption after an acute lipid challenge in mice. Finally, the CHCI3 fraction ameliorates various parameters of HFD-induced obesity mice, including body weight gain and serum levels of TG and glucose. Data obtained from the results obviously indicated that A. rossii prevents HFD-induced hyperlipidemia as well as obesity in mice possibly by inhibiting DGAT activity. We suggest that A. rossii MeOH extract and its CHCI3 fraction would be a useful material for the therapy of hyperlipidemia.